Opendata, web and dolomites

CL-IO SIGNED

Commercial feasibility of non-pathogenic Clostridium-Mediated Cancer Immunotherapy: leveraging the presence of tumour hypoxia & necrosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CL-IO project word cloud

Explore the words cloud of the CL-IO project. It provides you a very rough idea of what is the project "CL-IO" about.

team    necrosis    incidence    watch    14    combating    worldwide    technological    inhibitor    inclusion    experts    market    tumour    dictated    limitation    malignancies    immune    mortality    minority    strategies    patients    antibody    benefit    suppression    regions    prof    start    modality    accelerator    stereotactic    powerful    escape    tumors    https    com    tumours    delivering    despite    gain    necrotic    l19    prepare    innovative    position    immunotherapeutic    overcome    poc    immunocytokine    urgency    cl    io    optimal    site    commercial    bacteria    business    lung    vimeo    therapy    push    mechanisms    lambin    cellular    exact    commercialisation    therapeutic    off    positioning    hypoximmuno    modified    feasibility    immunotherapeutics    immunotherapy    ip    sought    producing    checkpoint    clostridium    weapons    precision    erc    solid    model    hypoxic    genetically    251022032    break    rates    routes    cancer    hypoxia    colonise    spin    cancers    radiotherapy    strategic    release    respect    first    act    limited    trimodal    immunotherapies    factories    il2    agents    strategy    selectively    proven    proof   

Project "CL-IO" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT MAASTRICHT 

Organization address
address: Minderbroedersberg 4-6
city: MAASTRICHT
postcode: 6200 MD
website: http://www.maastrichtuniversity.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 150˙802 €
 EC max contribution 150˙000 € (99%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) coordinator 150˙000.00

Map

 Project objective

Immunotherapeutic strategies are powerful weapons in combating malignancies. However, only a minority of patients benefit from this therapeutic modality, as tumours develop mechanisms of immune escape and suppression and uptake of (antibody-based) agents in tumors is limited. The urgency of investigating novel strategic approaches is dictated by the high incidence and mortality rates of cancer worldwide. Lung cancer, in particular, is the leading cancer with respect to incidence and mortality (14% of new cancers). In the ERC Advanced “HYPOXIMMUNO”, Prof. Lambin and his team have investigated the trimodal therapy involving high precision Stereotactic Radiotherapy, hypoxia/necrosis targeting and tumour specific immunotherapy (immunocytokine L19-IL2 to “push the accelerator” with a checkpoint inhibitor to “release the break”). Despite promising results, the delivery of immunotherapeutics to the tumour site has proven to be challenging. Prof. Lambin and his team have sought to overcome this limitation with the inclusion of genetically-modified Clostridium bacteria as optimal delivery system capable of effectively delivering immunotherapeutics within the tumour. These Clostridium-bacteria selectively colonise the hypoxic/necrotic regions present in solid tumours and act as cellular factories capable of continuously producing tumour-specific immunotherapies within the tumour (watch https://vimeo.com/251022032 ). In this ERC PoC project, a team of technological and commercial experts will investigate the commercial feasibility of this innovative approach. We will prepare the first steps towards the start-up of a spin-off, by defining the exact business strategy, model and positioning for commercial success. We will develop the business strategy based on the technological aspects, the market needs and trends, and the IP-position. During CL-IO, we will gain technical and commercial proof-of-concept, providing the necessary information for potential commercialisation routes.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CL-IO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CL-IO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

MYMOVE (2019)

Migrant youth mobility in Europe: patterns, processes and consequences

Read More  

ELISA (2020)

The Emergence of Language in Social Interaction

Read More  

RESOURCE Q (2019)

Efficient Conversion of Quantum Information Resources

Read More